Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2012

View Archived Issues

Scientists in Germany develop novel model for chronic lung allograft damage

Chinese study assesses plasma amino acid profiles as predictors of depression severity

FDA issues complete response letter for Relistor sNDA

New European approval for Afinitor

AnGes plans Japanese study of gene therapy for lymphedema

New siRNA delivery method achieves selective targeting for prevention of organ rejection

Novel NADK inhibitors discovered in France

Cadila Healthcare divulges novel LDL receptor ligands

New antiviral agents presented

Novel arginase inhibitors disclosed by Corridor Pharmaceuticals

Novel acetyl-CoA carboxylase inhibitors developed in India

Merck Serono creates first spin-off from Entrepreneur Partnership Program

Tonix Pharmaceuticals completes study of sublingual TNX-102

FDA grants priority review to cabozantinib NDA

SNS01-T obtains FDA orphan drug status in two new indications

Japanese team designs new MGAT2 inhibitors

Palau Pharma signs exclusive agreement with Sensorion Pharmaceuticals

Auxilium Pharmaceuticals reports topline data on Xiaflex

Amgen profiles progress of second quarter 2012

New model uses transgenic pigs to study hepatocyte transplants

Gilead Sciences reports results for the second quarter of 2012

EC approves first drug for nonradiographic severe axial spondyloarthritis

Bristol-Myers Squibb updates progress of second quarter 2012

FDA issues complete response letter for rilonacept sBLA

Ariad submits NDA for ponatinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...